Search
Fenfluramine
go.drugbank.com/drugs/DB00574ApprovedIllicitInvestigationalWithdrawnDravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency an...
International brands: Ponderax PACategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesGSK-1521498
go.drugbank.com/drugs/DB12886InvestigationalGSK1521498 has been used in trials studying the treatment of Obesity and Alcoholism.
Categories: Receptors, Opioid, muGlipizide
go.drugbank.com/drugs/DB01067ApprovedInvestigational[L6712] Because sulfonylureas require functional pancreatic beta cells for their therapeutic effectiveness, sulfonylureas are more commonly used for early-stage type 2 diabetes when there is no progressed
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesSynonyms: 1-cyclohexyl-3-({p-[2-(5-methylpyrazinecarboxamido)ethyl]phenyl}sulfonyl)urea, N-{4-[β-(5-methylpyrazine-2-carboxamido)ethyl]benzenesulphonyl}-N'-cyclohexylureaDifelikefalin
go.drugbank.com/drugs/DB11938ApprovedInvestigational[A237620] Options for therapy are limited - with no FDA-approved treatments, off-label [gabapentin] was the most evidence-based and widely available treatment.
Difluocortolone
go.drugbank.com/drugs/DB09095ApprovedWithdrawnIt was submitted to the FDA in July 1984 by the pharmaceutical company Schering AG.[L1082]
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersLicofelone
go.drugbank.com/drugs/DB04725ExperimentalAlthough phase III trials have been successfully completed in OA patients no dates for regulatory submission have yet been given.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 InhibitorsNorelgestromin
go.drugbank.com/drugs/DB06713ApprovedInvestigationalIt is administered transdermally in combination with the estrogen [ethinyl estradiol], delivering both hormones systemically over a 7-day wear period.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesDenosumab
go.drugbank.com/drugs/DB06643ApprovedInvestigationalJubbonti® (denosumab-bbdz)[L53058]—were approved by the FDA in March 2024 for all indications of the reference products Xgeva® and Prolia®; Both biosimilars also received marketing authorization in the EU
Azilsartan medoxomil
go.drugbank.com/drugs/DB08822ApprovedInvestigationalAlthough there is no clinical significance yet determined, azilsartan medoxomil may have potential off-label uses in patients with a history of myocardial infarction or heart failure.[A232863]
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesRESP301
go.drugbank.com/drugs/DB16497InvestigationalRESP301 was under investigation in clinical trials for various conditions. It was studied in community patients at risk of viral infections, including SARS-CoV-2, in a terminated trial (NCT04858451) and adults with rifampicin-susceptible...